Purchase this article with an account.
Dai Miyazaki, Grace Liu, Leslie Clark, Santa Jeremy Ono; Prevention of Acute Allergic Conjunctivitis and Late-Phase Inflammation with Immunostimulatory DNA Sequences. Invest. Ophthalmol. Vis. Sci. 2000;41(12):3850-3855.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
purpose. To evaluate the therapeutic potential of immunostimulatory sequence
oligodeoxynucleotides (ISS-ODN) administration in ocular allergy, using
a mouse model of ragweed-specific conjunctivitis.
methods. A murine model of allergic conjunctivitis involving SWR/J mice
sensitized and challenged with short ragweed was used to test
immunostimulatory DNA sequences for therapeutic potential. ISS-ODN or
control ODN (0.1 mg/mouse) was administered intraperitoneally or
topically to the conjunctiva 3 days before final allergen challenge.
Multiple parameters of clinical symptoms evident during the acute-phase
reaction and the cellular components of the late-phase reaction were
evaluated in both groups of mice.
results. All parameters of clinical symptoms were markedly inhibited after
intraperitoneal injection of ISS-ODN, whereas topical application to
the conjunctiva did not inhibit clinical symptoms significantly.
Remarkably, a single topical treatment with ISS-ODN (as well as by
intraperitoneal injection) completely inhibited both eosinophilia and
neutrophilia in the late-phase reaction.
conclusions. Systemic or conjunctival administration of ISS-ODN was shown to
significantly inhibit allergic responses in this mouse model. This
indicates that ISS-ODN may be an effective form of immunotherapy for
this class of allergic disease.
This PDF is available to Subscribers Only